Which of the following is a serious risk associated with SSRIs?

Suicidal thoughts are recognized as a serious risk associated with selective serotonin reuptake inhibitors (SSRIs), particularly in certain populations, such as children, adolescents, and young adults. When SSRIs are initiated, there can be an increase in suicidal ideation or behavior, especially during the early weeks of treatment or when doses are adjusted. This phenomenon is believed to be related to the time it takes for SSRIs to alter mood significantly; in the interim, patients may experience increased agitation or restlessness, potentially heightening suicidal thoughts.

Health professionals must monitor patients closely during the initial treatment period, paying attention to any changes in mood, behavior, or feelings of hopelessness. The Boxed Warning provided by the FDA for SSRIs emphasizes this risk, highlighting the importance of patient and caregiver education about potential side effects, ensuring timely intervention if concerning symptoms arise.

Other conditions, like severe constipation, hypotension, and severe allergic reactions, can occur with SSRIs but are generally less common and not considered as significant or serious risks as suicidality. Monitoring for side effects is essential, but the heightened risk of suicidality is a critical aspect that caregivers and medical professionals must prioritize.